The Oncology Institute, Inc. TOI Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -7.2%+8.1pp | -15.3%+8.5pp | -23.8%+8.7pp | -32.5%-9.9pp | |
| Net margin | -12.1%+4.4pp | -16.4%+9.2pp | -25.6%— | —— | |
| EBITDA margin | -5.8%+7.9pp | -13.7%+8.3pp | -21.9%+8.8pp | -30.7%-9.8pp | |
| Free cash flow margin | -6%— | —— | -12.6%+14.0pp | -26.6%-9.1pp | |
| Returns | |||||
| Return on assets | -35.9%-2.1pp | -33.9%+1.4pp | -35.3%— | —— | |
| Return on invested capital | -54.8%-0.3pp | -54.5%-11.8pp | -42.7%— | —— | |
| Efficiency | |||||
| Asset turnover | 3×+0.9× | 2.1×+0.7× | 1.4×+0.3× | 1.1×-0.4× | |
| Liquidity | |||||
| Current ratio | 1.6×-0.6× | 2.2×-2.0× | 4.1×-0.3× | 4.4×-0.8× | |
| Quick ratio | 1.4×-0.6× | 2×-1.8× | 3.7×-0.3× | 4.1×-0.9× | |
| Cash ratio | 0.5×-0.5× | 1×0.0× | 1×+0.5× | 0.5×-3.4× | |
| Leverage | |||||
| Debt-to-assets | 0.6×-0.1× | 0.7×+0.1× | 0.6×+0.2× | 0.4×+0.4× | |
| Interest coverage | -3.2×+4.8× | -8×+3.3× | -11.4×— | —— | |
| Per Share | |||||
| Book value per share | -$0.17-456% | $0.05-93.8% | $0.77-49.4% | $1.53-2.8% | |
| Valuation | |||||
| Market capitalization | $511.91M+133% | $23.35M-84.4% | $149.88M+24.9% | $120.04M-83.2% | |
| Enterprise value | $586.58M+108% | $96.93M-59.0% | $236.2M+10.1% | $214.45M-64.2% | |
| Price / sales | 0.9×+0.4× | 0.1×-0.4× | 0.5×0.0× | 0.5×-3.0× | |
| EV / sales | 1.1×+0.4× | 0.2×-0.5× | 0.7×-0.1× | 0.8×-2.1× | |
| Free cash flow yield | -5.5%— | —— | -27.3%+28.8pp | -56.1%-51.1pp | |
| Earnings yield | -8.5%+20.8pp | -277%-222pp | -55.4%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do The Oncology Institute, Inc.'s ratios come from?
- Every ratio is computed from The Oncology Institute, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
